Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ustekinumab success in refractory Crohn’s disease
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Tcelna® (imilecleucel-T)
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Change in the clinical development program for laquinimod
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Glatiramer acetate in the treatment of multiple sclerosis
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Spin-offs: Meet the structure specialists
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.

Pages